NSE: LUPIN | BSE: 500257

Strong Performer, Getting Expensive

Download real time

2338.90 23.80 (1.03%)

Near 52W High of ₹2377.60

925.3K NSE+BSE Volume

NSE 15 Apr, 2026 3:55 PM (IST)

106,929.6

Market Cap

High in industry

Beta 1Year

Very Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

16 Feb 2026

2338.90

1.03%

Dependency on US exclusivity rising

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Beat in Q3FY26 vs our expectation was mainly driven by stellar performance in the US region, posting revenue of USD 350mn (up 46.8% YoY). Apart from a few seasonal products, sales in US were largely led by Tolvaptan, Mirabegron and Spiriva.

Lupin has gained 20.73% in the last 6 Months

Lupin Ltd.

16 Feb 2026

2338.90

1.03%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,460/share.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

15 Feb 2026, 12:00AM

2338.90

1.03%

Lupin (BUY): Multiple growth levers for multiple years

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /APAT reported 8.2%/13.1%/25% above our estimates. EBITDA Margin reported 130 bps above our estimates

Lupin has gained 20.73% in the last 6 Months

Lupin Ltd.

14 Feb 2026, 12:00AM

2338.90

1.03%

Strong execution drives margin to decade high

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) posted a better-than-expected financial performance in 3QFY26, with 6%/16%/22% beat on revenues/EBITDA/PAT. Robust traction in US and other developed markets helped LPC sustain profitable growth momentum in 3Q.

Lupin has gained 20.73% in the last 6 Months

Lupin Ltd.

16 Jan 2026

2338.90

1.03%

Healing and Health

Buy: Lupin Ltd.

FundsIndia

U.S. business grew ~41% YoY in Q2FY26, led by specialty & complex launches. Europe up ~27% YoY; Other Developed Markets up ~19%.

Lupin Ltd. has an average target of 2392.73 from 11 brokers.

Lupin Ltd.

25 Nov 2025

2338.90

1.03%

LUPIN LIMITED

Buy: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

In Q2FY26, Lupin reported a consolidated revenue of Rs. 7,048cr, up 24.2% YoY, Lupin's India segment revenue rose 3.4% YoY to Rs. 2,078cr, led by an 8.8% growth in Rx business, strong chronic therapy momentum and robust volume growth,...

Lupin Ltd. has an average target of 2392.73 from 11 brokers.

Lupin Ltd.

13 Nov 2025

2338.90

1.03%

Record quarter with broad-based growth, strong U.S. momentum, and sharp margin expansion

Buy: Lupin Ltd.

Deven Choksey

Lupin remains well-positioned to sustain its strong growth trajectory, supported by a healthy specialty pipeline in the U.S., improved product mix, and operating leverage gains.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

11 Nov 2025

2338.90

1.03%

Lupin Ltd

Buy: Lupin Ltd.

Recommendation Target

ICICI Direct

Niche launches in the US drive numbers; future pipeline key for sustainability Earning momentum strong till FY26; apparent slowdown in FY27 but pipeline buildup to continue- Strong growth was attributable US launches under exclusivity (gMyrbetriq, gTolvaptan and gSpiriva) and launches across regions. India was impacted due to lower tender sales in Institutional business. The company has maintained the strong EBITDA margins trajectory mainly driven by strong GPM performance. The...